Recent Advances in Lung Cancer: Summary of Presentations from the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2011

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 Kwak, 2010, Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448 Kris, 2011, Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC), J Clin Oncol, 29, 10.1200/jco.2011.29.18_suppl.cra7506 Maemondo, 2010, Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530 Rosell, 2011, Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.7503 Zhou, 2011, J Clin Oncol, 29 Nakamura, 2007, c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis, Cancer Sci, 98, 1006, 10.1111/j.1349-7006.2007.00493.x Iyer, 1990, Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene, Cell Growth Differ, 1, 87 Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478 Spigel, 2011, Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.7505 Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945 Shaw, 2009, Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK, J Clin Oncol, 27, 4247, 10.1200/JCO.2009.22.6993 Shaw, 2011, Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.7507 Whitesell, 1994, Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation, Proc Natl Acad Sci U S A, 91, 8324, 10.1073/pnas.91.18.8324 Wong, 2011, An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC), J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.7500 Fidias, 2009, Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer, J Clin Oncol, 27, 591, 10.1200/JCO.2008.17.1405 Cappuzzo, 2010, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study, Lancet Oncol, 11, 521, 10.1016/S1470-2045(10)70112-1 Kabbinavar, 2010, J Clin Oncol, 28, 10.1200/jco.2010.28.15_suppl.7526 Perol, 2010, Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study, J Clin Oncol, 28, 10.1200/jco.2010.28.15_suppl.7507 Paz-Ares, 2011, PARAMOUNT: phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC), J Clin Oncol, 29, 10.1200/jco.2011.29.18_suppl.cra7510 Zhang, 2011, J Clin Oncol, 29, 10.1200/JCO.2010.31.6265 Brugger, 2009, Molecular markers and clinical outcome with erlotinib: results from the phase III placebo-controlled SATURN study of maintenance therapy for advanced NSCLC, J Thorac Oncol, 4, S348 Stinchcombe, 2011, Maintenance therapy in advanced non-small cell lung cancer: current status and future implications, J Thorac Oncol, 6, 174, 10.1097/JTO.0b013e318200f9c5 Strauss, 2008, Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups, J Clin Oncol, 26, 5043, 10.1200/JCO.2008.16.4855 Strauss, 2011, Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.7015 Butts, 2010, Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10, J Clin Oncol, 28, 29, 10.1200/JCO.2009.24.0333 Kreuter, 2011, Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.7002 Cuffe, 2011, Adoption of adjuvant chemotherapy (ACT) for non-small cell lung cancer (NSCLC) in the elderly: a population-based outcomes study, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.7012 Gu, 2011, Platinum-based adjuvant chemotherapy (ACT) in elderly patients with non-small cell lung cancer (NSCLC) in the SEER-Medicare database: comparison between carboplatin- and cisplatin-based regimens, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.7014 Jotte, 2011, Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy, J Clin Oncol, 29, 287, 10.1200/JCO.2010.29.8851 Jotte, 2011, Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC), J Clin Oncol, 29, 10.1200/JCO.2010.29.8851 Mitsudomi, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, The Lancet Oncol, 11, 121, 10.1016/S1470-2045(09)70364-X Ciuleanu, 2009, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study, Lancet, 374, 1432, 10.1016/S0140-6736(09)61497-5